Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy

Diabetologia

Volumn 56, Issue 2, 2013, Pages 252-258

  Andersen, C D ^a   Bennet, L ^a   Nystrom L ^b   Lindblad, U ^c   Lindholm, E ^a   Groop, L ^a   Rolandsson, O ^b  

^a LUND UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

GAD isoform 65; HbA1c; Latent autoimmune diabetes in adults

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIET THERAPY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; KINESIOTHERAPY; LATENT AUTOIMMUNE DIABETES; LATENT AUTOIMMUNE DIABETES IN ADULT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; AUTOIMMUNE DISEASE; BLOOD; DRUG EFFECT; GLUCOSE BLOOD LEVEL; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

MLCS; MLOWN;

EID: 84878777575     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2759-y     Document Type: Article

References (21)

1. Tuomi T, Carlsson A, Li H et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157
2. Davis TM, Wright AD, Mehta ZM et al (2005) Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 48:695-702
3. Bakhtadze E, Cervin C, Lindholm E et al (2008) Common variants in the TCF7L2 gene help to differentiate autoimmune from non-autoimmune diabetes in young (15-34 years) but not in middle-aged (40-59 years) diabetic patients. Diabetologia 51:2224-2232
4. Desai M, Cull CA, Horton VA et al (2007) GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia 50:2052-2060
5. Thunander M, Petersson C, Jonzon K et al (2008) Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract 82:247-255
6. Kobayashi T, Nakanishi K, Murase T, Kosaka K (1996) Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45:622-626
7. Maruyama T, Tanaka S, Shimada A et al (2008) Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 93:2115-2121
8. Norberg M, Wall S, Boman K, Weinehall L (2010) The Vasterbotten Intervention Programme: background, design and implications. Glob Health Action Mar 22:3
9. Rolandsson O, Norberg M, Nystrom L et al (2012) How to diagnose and classify diabetes in primary health care: lessons learned from the Diabetes Register in Northern Sweden (DiabNorth). Scand J Prim Health Care 30:81-87
10. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553
11. Fourlanos S, Dotta F, Greenbaum CJ et al (2005) Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48:2206-2212
12. Brophy S, Yderstraede K, Mauricio D et al (2008) Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 31:439-441
13. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577-1596
14. Lindholm E, Hallengren B, Agardh CD (2004) Gender differences in GAD antibody-positive diabetes mellitus in relation to age at onset, C-peptide and other endocrine autoimmune diseases. Diabetes Metab Res Rev 20:158-164
15. Lundgren VM, Isomaa B, Lyssenko V et al (2010) GAD antibody positivity predicts type 2 diabetes in an adult population. Diabetes 59:416-422
16. Falorni A, Ortqvist E, Persson B, Lernmark A (1995) Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Methods 186:89-99
17. Grubin CE, Daniels T, Toivola B et al (1994) A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 37:344-350
18. Daka B, Svensson MK, Lernmark Å, Mincheva-Nilsson L, Hallmans G, Rolandsson O (2009) Low agreement between radio binding assays in analyzing glutamic acid decarboxylase (GAD65Ab) autoantibodies in patients classified with type 2 diabetes. Autoimmunity 42:1-8
19. Brophy S, Brunt H, Davies H, Mannan S, Williams R (2007) Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev Art no.: CD006165. DOI: 10.1002/14651858.CD006165.pub2
20. Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G (2001) High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 86:3032-3038
21. Buzzetti R, Di Pietro S, Giaccari A et al (2007) High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 30:932-938